Owners, management and financials
CVR: 32328768
Secondary names: COPHARMA ApS, Amneal Nordic ApS
Previous names: COPHARMA ApS, AMNEAL NORDIC ApS
EUR 453,392
Revenue
Net result: EUR 21,589
Aristo Pharma GmbH (100%)
CVR · view owners
John Hudson Kriwet
Board: John Hudson Kriwet (chair) and 2 members
CVR · view management
Active
Founded 8 February 2011
CVR · view overview
8 employees
CVR · 2018
Director role ended: Sascha Rauschke
CVR · 31/03/2024
View the full event history
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 8 employees (2018). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.
Selskabets formål er at sælge kvalitetslægemidler til apoteker i de nordiske lande samt hermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 453 t. EUR | 22 t. EUR | 3 mio. EUR | 185 t. EUR | 3 | |
| 202401/01/2024 – 31/12/2024 | 529 t. EUR | 25 t. EUR | 2.5 mio. EUR | 163 t. EUR | 3 | |
| 202301/01/2023 – 31/12/2023 | - | 26 t. EUR | 2 mio. EUR | 138 t. EUR | 3 | |
| 202201/01/2022 – 31/12/2022 | - | 52 t. EUR | 1.4 mio. EUR | 112 t. EUR | 5 | |
| 202101/01/2021 – 31/12/2021 | - | 45 t. EUR | 495 t. EUR | 61 t. EUR | 7 | |
| 202001/01/2020 – 31/12/2020 | - | 62 t. EUR | 332 t. EUR | -1.3 mio. EUR | 7 | |
| 201901/01/2019 – 31/12/2019 | - | -286 t. EUR | 760 t. EUR | -1.3 mio. EUR | 6 | |
| 201801/01/2018 – 31/12/2018 | - | -1.9 mio. EUR | 3 mio. EUR | -3 mio. EUR | 8 | |
| 201701/01/2017 – 31/12/2017 | - | -5 mio. EUR | 6.8 mio. EUR | -1.2 mio. EUR | 10 | |
| 201601/01/2016 – 31/12/2016 | - | -2.1 mio. EUR | 6.2 mio. EUR | -4.7 mio. EUR | 12 | |
| 201501/01/2015 – 31/12/2015 | - | -1.6 mio. EUR | 3.2 mio. EUR | -2.7 mio. EUR | 11 | |
| 201401/01/2014 – 31/12/2014 | - | -1.7 mio. EUR | 3.4 mio. EUR | -1.1 mio. EUR | 12 | |
| 201201/10/2011 – 30/09/2012 | - | -428 t. | 1.5 mio. | -484 t. | - |
Compared to 293 companies in Engroshandel med læge- og hospitalsartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of Aristo Pharma Nordic ApS is 32328768.
Aristo Pharma Nordic ApS is owned by Aristo Pharma GmbH.
The management of Aristo Pharma Nordic ApS consists of John Hudson Kriwet.
The board of Aristo Pharma Nordic ApS consists of John Hudson Kriwet, Jannes Paul Beeskow and Robert Maciej Szymanski, with John Hudson Kriwet as chair.
In 2025, Aristo Pharma Nordic ApS reported revenue of EUR 453,392.
Aristo Pharma Nordic ApS had 8 employees in 2018 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Aristo Pharma Nordic ApS has published its annual report for 2025. Revenue came to DKK 453,392, and the net result was DKK 21,589.
Contact info changed: new phone: 70707982, new email: [email protected], new website: www.amnealnordic.com (January 15, 2026).
Aristo Pharma Nordic ApS has published its annual report for 2024. Revenue came to DKK 528,984, and the net result was DKK 25,190.
As of May 30, 2025, BAKER TILLY DENMARK GODKENDT REVISIONSAKTIESELSKAB has stepped down as auditor of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2023. Gross profit came to DKK 326,645, and the net result was DKK 25,848.
As of March 31, 2024, Jannes Paul Beeskow has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 31, 2024, Sascha Rauschke has left the board of directors of Aristo Pharma Nordic ApS.
As of March 31, 2024, John Hudson Kriwet is registered as director of Aristo Pharma Nordic ApS.
As of March 31, 2024, Sascha Rauschke has stepped down as director of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2022. Gross profit came to DKK 717,126, and the net result was DKK 51,525.
As of January 12, 2023, Robert Maciej Szymanski has joined the board of directors of Aristo Pharma Nordic ApS.
As of January 12, 2023, Kenneth Pedersen has left the board of directors of Aristo Pharma Nordic ApS.
As of December 31, 2022, Sascha Rauschke is registered as director of Aristo Pharma Nordic ApS.
As of December 31, 2022, Kenneth Pedersen has stepped down as director of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2021. Gross profit came to DKK 789,373, and the net result was DKK 45,333.
As of December 11, 2021, BAKER TILLY DENMARK GODKENDT REVISIONSAKTIESELSKAB has been appointed auditor of Aristo Pharma Nordic ApS.
As of December 11, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Aristo Pharma Nordic ApS.
As of August 30, 2021, Kenneth Pedersen has joined the board of directors of Aristo Pharma Nordic ApS.
As of August 18, 2021, Christian Jaaks has left the board of directors of Aristo Pharma Nordic ApS.
As of August 18, 2021, Kenneth Pedersen is registered as director of Aristo Pharma Nordic ApS.
As of August 18, 2021, Sascha Rauschke has stepped down as director of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2020. Gross profit came to DKK 805,029, and the net result was DKK 62,127.
As of March 15, 2021, Christian Jaaks has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 15, 2021, John Hudson Kriwet has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 15, 2021, Hasnain Nasir Butt has left the board of directors of Aristo Pharma Nordic ApS.
As of March 15, 2021, Sascha Rauschke is registered as director of Aristo Pharma Nordic ApS.
As of March 15, 2021, Hasnain Nasir Butt has stepped down as director of Aristo Pharma Nordic ApS.
As of March 14, 2021, Christian Jaaks has left the board of directors of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2019. Gross profit came to DKK 469,744, and the net result was DKK -286,054.
As of December 5, 2019, Christian Jaaks has joined the board of directors of Aristo Pharma Nordic ApS.
As of December 5, 2019, Anton Alwin Karremann has left the board of directors of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2018. Gross profit came to DKK -948,611, and the net result was DKK -1,875,856.
Aristo Pharma Nordic ApS has published its annual report for 2017. Gross profit came to DKK -3,906,558, and the net result was DKK -5,014,436.
On October 26, 2017, the company changed its name from AMNEAL NORDIC ApS to Aristo Pharma Nordic ApS.
As of October 4, 2017, Hasnain Nasir Butt has joined the board of directors of Aristo Pharma Nordic ApS.
As of October 4, 2017, Sascha Rauschke has joined the board of directors of Aristo Pharma Nordic ApS.
As of October 4, 2017, Anton Alwin Karremann has joined the board of directors of Aristo Pharma Nordic ApS.
As of October 4, 2017, Chirag K Patel has left the board of directors of Aristo Pharma Nordic ApS.
As of October 4, 2017, Chintu Patel has left the board of directors of Aristo Pharma Nordic ApS.
As of October 4, 2017, János Váczi has left the board of directors of Aristo Pharma Nordic ApS.
As of October 4, 2017, Hasnain Nasir Butt is registered as director of Aristo Pharma Nordic ApS.
As of October 4, 2017, János Váczi has stepped down as director of Aristo Pharma Nordic ApS.
As of October 4, 2017, is registered as an owner of Aristo Pharma Nordic ApS with an ownership share of 100%.
Aristo Pharma Nordic ApS has published its annual report for 2016. Gross profit came to DKK -474,855, and the net result was DKK -2,070,042.
As of December 16, 2016, János Váczi is registered as director of Aristo Pharma Nordic ApS.
As of December 16, 2016, Lena Storm Christensen has stepped down as director of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2015. Gross profit came to DKK 145,002, and the net result was DKK -1,602,082.
As of December 31, 2015, Lena Storm Christensen is registered as director of Aristo Pharma Nordic ApS.
As of December 31, 2015, Svend Aage Johansen has stepped down as adm. dir. of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2014. Gross profit came to DKK -733,672, and the net result was DKK -1,668,647.
As of April 28, 2015, János Váczi has joined the board of directors of Aristo Pharma Nordic ApS.
As of April 10, 2015, János Váczi has left the board of directors of Aristo Pharma Nordic ApS.
As of March 17, 2015, János Váczi has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 17, 2015, Chirag K Patel has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 17, 2015, Chintu Patel has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 17, 2015, Joseph Todisco has left the board of directors of Aristo Pharma Nordic ApS.
As of March 17, 2015, Peter Prock has left the board of directors of Aristo Pharma Nordic ApS.
As of March 16, 2015, János Váczi has left the board of directors of Aristo Pharma Nordic ApS.
As of December 30, 2014, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Aristo Pharma Nordic ApS.
As of December 30, 2014, EY Danmark A/S has stepped down as auditor of Aristo Pharma Nordic ApS.
On May 12, 2014, the company changed its name from COPHARMA ApS to AMNEAL NORDIC ApS.
Aristo Pharma Nordic ApS has published its interim report for the period October 1, 2012 – December 31, 2013.
As of April 14, 2014, EY Danmark A/S has been appointed auditor of Aristo Pharma Nordic ApS.
As of April 14, 2014, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Aristo Pharma Nordic ApS.
As of April 14, 2014, János Váczi has joined the board of directors of Aristo Pharma Nordic ApS.
As of April 14, 2014, Joseph Todisco has joined the board of directors of Aristo Pharma Nordic ApS.
As of April 14, 2014, Peter Prock has joined the board of directors of Aristo Pharma Nordic ApS.
As of March 12, 2013, Svend Aage Johansen is registered as adm. dir. of Aristo Pharma Nordic ApS.
As of March 12, 2013, John Morell Frellsen has stepped down as director of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS has published its annual report for 2012. Gross profit came to DKK -297,210, and the net result was DKK -428,002.
As of May 1, 2012, John Morell Frellsen is registered as director of Aristo Pharma Nordic ApS.
As of May 1, 2012, Peter Lassen has stepped down as director of Aristo Pharma Nordic ApS.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Aristo Pharma Nordic ApS.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of Aristo Pharma Nordic ApS.
As of February 8, 2011, A/S PSE NR. 4820 has been appointed auditor of Aristo Pharma Nordic ApS.
As of February 8, 2011, Peter Lassen is registered as director of Aristo Pharma Nordic ApS.
Aristo Pharma Nordic ApS was founded on February 8, 2011.
Companies in the same industry and area
CVR 45320618
CVR 27478700
CVR 13902992
CVR 45224260
CVR 51619811
